- Business Wire•2 days agoPost-Hoc Analysis of Open-Label Extension Study Assesses the Use of ONFI® (Clobazam) CIV and the Potential for Tolerance
Results from a post-hoc analysis of an open-label extension study evaluating the potential of developing tolerance to adjunctive ONFI CIV in patients with Lennox-Gastaut syndrome were published online in Neurology.
- Bloomberg•7 days ago
H. Lundbeck A/S dropped the most in almost four years after its experimental Alzheimer’s drug failed to meet targets in a final-stage patient trial.
- CNBC•8 days ago
The company's lead Alzheimer's candidate is similar to the product that disappointed in a competitor's clinical trials.
H. Lundbeck A/S (LUN.CO)
Copenhagen - Copenhagen Delayed Price. Currency in DKK
|Day's Range||214.60 - 219.00|
|52wk Range||180.70 - 290.50|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-33.39|
|Avg Vol (3m)||309,683|
|Dividend & Yield||N/A (N/A)|